. 2011 May 17;2011:840248. doi: 10.1155/2011/840248

Table 4.

Health-related quality outcomes: average treatment effects for patients receiving advanced practice registered nurse intervention, by dose, versus usual care.

APRN dose	Period	Effect (d)	95% CI	P	Effect (d)	95% CI	P	Effect (d)	95% CI	P	Effect (d)	95% CI	P	Effect (d)	95% CI	P
		Mental composite			Physical Composite			Mental health			General health			Social functioning
Low	Baseline to 3 M	1.25	−1.7, 4.2	.42	−0.55	−3.7, 2.6	.73	0.19	−0.2, 0.6	.40	−0.01	−0.4, 0.4	.94	−0.01	−0.5, 0.5	.94
	3 M to 6 M	0.59	−2.5, 3.6	.70	−1.75	−4.9, 1.4	.27	0.01	−0.4, 0.4	.95	−0.10	−0.6, 0.4	.67	−0.12	−0.7, 0.4	.65
	6 M to 12 M	0.84	−2.5, 4.1	.61	0.44	−3.1, 3.9	.80	0.19	−0.2, 0.6	.43	−0.15	−0.6, 0.4	.55	0.01	−0.5, 0.6	.97
	Baseline to 12 M	2.99	−0.2, 6.2	.07	−3.60	−7.3, 0.1	.05	0.56	0.4, 0.6	.76	−0.19	−0.7, 0.3	.47	0.12	−0.5, 0.7	.70

Moderate	Baseline to 3 M	0.57	−2.4, 3.5	.71	−0.11	−3.3, 3.0	.94	0.01	−0.4, 0.4	.98	0.15	−0.3, 0.6	.50	0.03	−0.5, 0.5	.94
	3 M to 6 M	0.90	−1.9, 3.7	.53	−1.12	− 4.0, 1.8	.45	−0.13	−0.5, 0.3	.54	−0.07	−0.5, 0.4	.75	−0.04	−0.5, 0.4	.88
	6 M to 12 M	1.46	−2.4, 5.3	.47	0.75	−3.3, 4.8	.71	0.27	−0.3, 0.8	.35	−0.12	−0.7, 0.5	.68	0.05	−0.6, 0.7	.88
	Baseline to 12 M	2.23	−0.8, 5.3	.15	0.16	−3.3, 3.6	.92	0.27	−0.2, 0.7	.27	−0.02	−0.5, 0.5	.95	−0.01	−0.6, 0.5	.94

High	Baseline to 3 M	−0.57	−2.9, 1.8	.64	1.90	−0.6, 4.4	.14	0.29	−0.1, 0.6	.12	0.45	0.1, 0.8	.02	−0.13	−0.6, 0.3	.54
	3 M to 6 M	5.55	1.4, 9.6	.01	−4.14	−8.3, 0.03	.05	0.46	−0.1, 1.0	.13	0.06	−0.6, 0.7	.85	0.35	−0.4, 1.1	.34
	6 M to 12 M	1.46	−2.8, 5.8	.50	2.90	−1.7, 7.5	.21	0.27	−0.3, 0.9	.39	−0.01	−07, 0.7	.97	−0.21	−0.9, 0.5	.57
	Baseline to 12 M	1.87	−0.8, 4.5	.17	2.60	−0.4, 5.6	.09	0.56	0.1, 0.9	.01	0.55	0.1, 1.0	.01	−0.37	−0.9, 0.1	.16

		Vitality			Role activities			Physical role			Bodily pain			Physical functioning

Low	Baseline to 3 M	0.10	−0.3, 0.5	.65	−0.02	−0.5, 0.4	.93	−0.15	−0.6, 0.3	.55	0.04	−0.3, 0.4	.82	0.12	−0.2, 0.4	.52
	3 M to 6 M	0.03	−0.4, 0.4	.87	0.03	−0.4, 0.4	.86	−0.02	−0.6, 0.5	.93	−0.12	−0.4, 0.2	.51	−0.26	−0.6, 0.1	.14
	6 M to 12 M	0.02	−0.4, 0.4	.92	0.12	−0.2, 0.5	.52	0.17	−0.3, 0.7	.49	0.18	−0.2, 0.5	.37	0.04	−0.3, 0.4	.83
	Baseline to 12 M	0.06	−0.4, 0.5	.79	0.21	−0.3, 0.7	.40	−0.38	−0.9, 0.1	.15	0.00	−0.4, 0.4	.98	−0.27	−0.7, 0.1	.16

Moderate	Baseline to 3 M	−0.12	−0.6, 0.3	.59	0.17	−0.3, 0.6	.46	−0.11	−0.6, 0.4	.65	0.08	−0.3, 0.4	.68	0.03	−0.3, 0.4	.85
	3 M to 6 M	0.15	−0.2, 0.5	.42	0.20	−0.1, 0.5	.23	−0.08	−0.6, 0.4	.74	−0.16	−0.5, 0.1	.35	−0.02	−0.3, 0.3	.93
	6 M to 12 M	−0.09	−0.6, 0.4	.73	0.23	−0.2, 0.7	.29	0.03	−0.5, 0.6	.92	0.42	−0.04, 0.9	.07	0.19	−0.3, 0.6	.40
	Baseline to 12 M	−0.16	−0.6, 0.3	.45	0.48	0.03, 0.9	.04	0.20	−0.3, 0.7	.43	0.38	−0.05, 0.8	.08	−0.08	−0.4, 0.3	.66

High	Baseline to 3 M	−0.26	−0.6, 0.1	.15	−0.14	−0.5, 0.2	.46	−0.05	−0.4, 0.3	.79	0.35	0.02, 0.6	.03	0.10	−0.2, 0.4	.46
	3 M to 6 M	−0.35	−0.9, 0.2	.19	0.51	0.04, 0.9	.03	0.01	−0.7, 0.7	.99	−0.35	−0.8, 0.1	.14	−0.31	−0.8, 0.2	.18
	6 M to 12 M	0.06	−0.5, 0.6	.83	0.63	0.1, 1.1	.01	0.37	−0.3, 1.0	.25	0.65	0.1, 1.1	.01	0.30	−0.2, 0.8	.22
	Baseline to 12 M	−0.36	−0.7, −0.01	.05	0.57	0.2, 0.9	.01	0.24	−0.2, 0.7	.27	0.57	0.18, 0.9	.00	−0.23	−0.1, 0.5	.15

Note: Health-related quality of life was measured with the medical outcomes study 12-item short form health survey. Positive effect values indicate improvement.